Compare ORC & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORC | NNNN |
|---|---|---|
| Founded | 2010 | 2021 |
| Country | United States | Germany |
| Employees | N/A | 27 |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2011 | N/A |
| Metric | ORC | NNNN |
|---|---|---|
| Price | $6.89 | $14.93 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 4.7M | 27.9K |
| Earning Date | 04-23-2026 | 04-07-2026 |
| Dividend Yield | ★ 17.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.28 | N/A |
| Revenue Next Year | $5.71 | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.42 | $10.50 |
| 52 Week High | $8.40 | $55.65 |
| Indicator | ORC | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 56.40 | 30.22 |
| Support Level | $6.84 | $14.66 |
| Resistance Level | $6.97 | $31.12 |
| Average True Range (ATR) | 0.12 | 2.81 |
| MACD | 0.04 | -0.34 |
| Stochastic Oscillator | 94.90 | 4.98 |
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).